Biogen’s diranersen, at its lowest dose, missed its primary mid-stage trial goal but showed benefits: cognitive decline improved in 5 of 6 Alzheimer assessment tools and the treatment significantly lowered toxic tau protein levels in the brain.
Biogen’s diranersen, at its lowest dose, missed its primary mid-stage trial goal but showed benefits: cognitive decline improved in 5 of 6 Alzheimer assessment tools and the treatment significantly lowered toxic tau protein levels in the brain.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
